MEDVi review: November 2026 prices, terms and what to verify
As of November 20, 2026, MEDVi’s current GLP-1 price is not confirmed here, because its compounded prices did not render on November 20, 2026 (the page showed template placeholders). This record shows no current figure rather than an older one presented as current; check the program’s own checkout before you enroll.
Released · Last reviewed · how we verify
Why no current price is shown
Its compounded prices did not render on November 20, 2026 (the page showed template placeholders). This site publishes no figure rather than an estimate or an outdated price presented as current. The August 2026 capture is kept in the open dataset as history, dated.
FDA warning letters
FDA’s warning-letter index lists warning letter 721455 (dated February 20, 2026, subject “False & Misleading Claims/Misbranded (Telehealth)”) to MEDVi; no close-out letter is listed. A warning letter is FDA’s formal notice of alleged violations, not a recall, ban or court finding.
Limitations: five things to get in writing before you pay
Ask for the all-in price at your current dose and at the maintenance dose; the amount charged today and whether it recurs monthly or is prepaid; the licensed pharmacy that fills the prescription; the cancellation and refund terms, word for word; and what happens to your price when the dose goes up. Compounded tirzepatide and semaglutide are not FDA-approved and are not the same products as Zepbound or Wegovy.
Frequently asked
Does MEDVi charge a membership fee?
MEDVi’s page did not show a membership fee that could be confirmed on November 20, 2026, so check the checkout summary for any recurring fee.
Does MEDVi take insurance?
Not for compounded medication. MEDVi is a cash-pay program in this dataset (August 2026 capture), and insurers do not cover compounded GLP-1s. If your plan covers Zepbound or Wegovy, check that first, because a covered brand prescription usually costs less than any cash price.
Which states does MEDVi serve?
MEDVi’s published coverage in the August 2026 capture was: not published. Telehealth prescribing depends on state licensing and changes often, so confirm your state at the start of the intake. The state pages list what each program publishes.
Sources
- FDA: Concerns with unapproved GLP-1 drugs used for weight loss (content current as of October 1, 2026; read November 20, 2026)
- Federal Register 91 FR 23431: proposed 503B bulks-list decision for semaglutide, tirzepatide and liraglutide (May 1, 2026; no final notice found as of November 20, 2026)
- Zepbound (tirzepatide) prescribing information on DailyMed (read November 20, 2026)
- Wegovy (semaglutide) prescribing information on DailyMed (read November 20, 2026)
- MEDVi pricing page (not readable on November 20, 2026)
- FDA warning letter 721455 to MEDVi (dated 2026-02-20, posted 2026-03-03; read November 20, 2026)